Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ETX-018810 · 2 trials · 3 indications
Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS), a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).
| Arm | Type | Description |
|---|---|---|
| ETX-018810 | EXPERIMENTAL | Drug: ETX-018810 BID for 4 weeks |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo BID for 4 weeks |
| Name | Type | Description |
|---|---|---|
| ETX-018810 | DRUG | Study Drug |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * The subject has pain consistent with a diagnosis of chronic lumbosacral radiculopathy due to injury of the lumbosacral nerve root(s) * The subject reports at least moderate pain intensity at screening. * The subject's onset of leg pain due to LSRP is at least 3 months * The su...
ETX-018810 is an investigational small molecule being developed for the treatment of diabetic peripheral neuropathic pain and lumbosacral radiculopathy. It is currently in Phase 2 clinical development and has not been approved by the FDA.
ETX-018810 is being developed by Climb Bio, Inc., a biopharmaceutical company traded under the ticker CLYM. The company is conducting clinical trials to evaluate the drug's efficacy and safety for neurological pain conditions.
ETX-018810 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one for diabetic peripheral neuropathic pain and one for lumbosacral radiculopathy. The drug remains investigational and is not yet approved.
ETX-018810 has been studied in two completed Phase 2 trials. NCT04688671 evaluated the drug in 167 patients with diabetic peripheral neuropathic pain, and NCT04778592 evaluated it in 149 patients with lumbosacral radiculopathy. Both trials were conducted in the United States.
No alternative names for ETX-018810 have been disclosed. The drug is identified solely by its code name ETX-018810 in clinical trial registries and by its developer, Climb Bio, Inc.